Dear editor
It is with interest that we read the paper “Treatment of allergic rhinitis and urticaria:
a review of the newest antihistamine drug bilastine” by Wang et al,1 in which the
authors provide insights into the burden of allergic diseases in the Asia-Pacific
region. Unfortunately, we found that the review provides some unsubstantiated information,
incorrect statements, and/or data inconsistencies as listed below.
The abstract states that bilastine “has very low potential for drug–drug interactions”;
however, the drug label lists interactions with ketoconazole, erythromycin, diltiazem,
and other intestinal efflux transporters, leading to 2–3-fold increases in drug maximum
serum concentration and area under the curve.2 Also, food interactions decrease bilastine’s
bioavailability by 30%, and the label recommendation is that it is taken 1 hour before
or 2 hours after intake of food or fruit juice.2
Table 2 presents a comparison between widely used antihistamines; however, the +++
score for bilastine’s H1-selectivity is not substantiated by the provided reference.2
Also, the highest Allergic rhinitis and its impact on asthma (ARIA)3 score attributed
to bilastine in Table 2 is in contrast to the information provided in Table 1; ie,
bilastine does not have higher potency or efficacy than other antihistamines (demonstrated
by several studies4–8); has clinically relevant interactions with food;2 has the same
indications and is effective on the same symptoms as other antihistamines;2 has only
one pediatric study;9 and its side effect profile2 and pharmacodynamic properties
are similar to other antihistamines.2 Many papers have reported that it has efficacy
and safety similar to cetirizine,4,7,8 desloratadine,5 fexofenadine,8 and levocetirizine.6
Table 2 contains incorrect information about the age groups of the pediatric indications
for cetirizine and levocetirizine, both of which are approved by the US Food and Drug
Administration for use in children as young as 6 months of age.10,11 Also, Table 2
inaccurately states that bilastine has no contraindications; according to the product
label,2 “hypersensitivity to the active substance or to any of the excipients […]”
is a contraindication.
The section “Bilastine efficacy” states that “the bilastine clinical trial program
was designed before the publication of the 2001 ARIA guidelines, so the patient inclusion
criteria were based on the former classification of seasonal and perennial allergic
rhinitis”; however, this seems to be in contrast to the information on www.ClinicalTrials.gov,
where the oldest bilastine study has a start date of April 2003;12 and the other bilastine
studies appear with start dates of 2004 through 2016.
A 12-month open-label safety analysis7 was described by the authors as “the longest
analysis to date with any antihistamine”; however, safety analyses from double-blind
randomized trials with cetirizine,13 loratadine,14 and levocetirizine15 over periods
of 12–18 months of treatment have already been published.
The section “No QTc prolongation” states that “to date, bilastine is the only commercially
available anti histamine that has been tested using the stringent ICH E/14 criteria
for effects on QT interval”. This is incorrect as a publication in 2007 presented
data from an ICH E-14 QT study with levocetirizine.16
The section “Lack of sedation” is misleading, since the bilastine product label2 lists
somnolence as a “common” adverse event (ie, occurring in 1%–10% of patients), which
is supported by data from several clinical trials reporting somnolence rates with
bilastine of 5.8%,6 3.9%,5 3.7%,7 and 1.8%.4
Figure 9 incorrectly presents that updosing with bilastine (80 mg) appears to have
2 to 3 times as many responders as those treated with desloratadine 20 mg or levocetirizine
20 mg. These data come from two clinical trials17,18 with completely different designs,
and therefore direct comparison between them is inappropriate. The bilastine data
come from a provocation test in subjects without symptoms at the time of study recruitment,
whereas the levocetirizine and desloratadine data come from a real clinical trial
with difficult-to-treat urticaria patients. Also, the original paper reported 12 patients
(~30%) as responders (symptom-free) on levocetirizine 20 mg and 1 responder (<3%)
on desloratadine 20 mg. In addition, Figure 9 uses another review article19 as a reference,
instead of the primary publications.17,18
As there is an unmet need in the management of allergic rhinitis in the Asia-Pacific
region, we welcome novel treatment options. However, based on the available data,
there is no evidence to suggest that bilastine provides superior clinical efficacy
to other commonly used second-generation antihistamines.4–8